Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2248 articles about Gilead Sciences, Inc.
-
Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies
2/13/2024
Long-time liver specialist Carrie Frenette says she won't ever forget the people she treated for hepatitis C (HCV) before 2013 - the year that the Food and Drug Administration (FDA) approved a Gilead medicine.
-
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
2/12/2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.
-
Gilead Sciences announced Monday it will purchase CymaBay Therapeutics and its investigational treatment seladelpar for primary biliary cholangitis, a type of liver disease that causes bile-duct damage.
-
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
2/9/2024
Gilead Sciences, Inc. announced the company has been named one of America’s Most JUST Companies.
-
Gilead Sciences is ending the development of magrolimab for the treatment of blood cancer following the FDA's placement of a clinical hold on all its programs related to the drug.
-
Hit with lower sales of its COVID-19 antiviral Veklury and the weak performance of its HIV franchise, Gilead Sciences reported a 4% year-over-year revenue loss in the fourth quarter of 2023.
-
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
2/6/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024.
-
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
2/6/2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
-
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
2/1/2024
Gilead Sciences, Inc. announced that Ted Love, MD, has been appointed to the company’s Board of Directors.
-
The new FDA-approved manufacturing process for Kite’s CAR-T cell therapy Yescarta will allow a 14-day turnaround compared to 16 days, the company announced on Tuesday.
-
Gilead Sciences and Arcus Biosciences have amended their collaboration agreement in an effort to accelerate an anti-TIGIT program, the companies announced Monday.
-
Gilead and Arcus Announce Amended Collaboration and Equity Investment
1/29/2024
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
-
TransCelerate BioPharma Organized for Growth and Bringing New Innovation and Collaboration to the Biopharmaceutical R&D Community
1/24/2024
TransCelerate BioPharma Inc., announced an expansion of its membership and appointment of the organization’s Chief Operating Officer.
-
While the FDA considers a T cell malignancy risk to be applicable to all commercial CAR-T therapies, Gilead Sciences’ Tecartus has a revised warning that potential adverse events “may” occur.
-
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
1/23/2024
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2023 financial results and guidance will be released on Tuesday, February 6, 2024 after the market closes.
-
Although the FDA did not outright say there is a causal secondary malignancy relationship, it asked BMS, Gilead, J&J and Novartis to add warnings to the labels of six CAR-T therapies noting the potential risks.
-
Gilead Provides Update on Phase 3 EVOKE-01 Study
1/22/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
-
Amid a hot antibody-drug conjugate market in oncology, Gilead Sciences announced Monday that its ADC Trodelvy did not reach a primary endpoint in a non-small cell lung cancer trial.
-
Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.
-
Gilead Sciences to Present at Upcoming January 2024 Investor Conference
12/21/2023
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference.